All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Subgroup Analysis Makes the Case for Earlier Liso-Cel Administration in R/R MCL

August 13th 2024

Manali Kamdar, MD, discusses responses with liso-cel according to prior lines of therapy and BTK inhibitor exposure in mantle cell lymphoma.

Toripalimab sNDA Under Review in China for Frontline Unresectable or Metastatic Melanoma

August 13th 2024

A sNDA seeking the approval of toripalimab for frontline use in patients with unresectable or metastatic melanoma is under review by the NMPA.

China’s NMPA Grants Breakthrough Therapy Designation to 9MW2821 in Advanced Urothelial Cancer

August 12th 2024

The Nectin-4–directed antibody-drug conjugate 9MW2821 has received breakthrough therapy designation in China for pretreated, advanced urothelial carcinoma.

Review Highlights the Need to Increase Germline BRCA Mutation Testing in Males

August 12th 2024

Kara N. Maxwell, MD, PhD, discusses the need to improve genetic testing rates for BRCA mutations in the male population.

Wearable-Captured Metrics and ePROs Prove Feasible as Digital Ecosystem in Waldenström Macroglobulinemia

August 12th 2024

Wearable-captured physiological metrics and electronic patient reported outcomes were practical and generated knowledge in Waldenström macroglobulinemia.

Atezolizumab/Bevacizumab Represents Potential Therapeutic Option in Child-Pugh B7 HCC

August 12th 2024

Atezolizumab plus bevacizumab showed efficacy in patients with hepatocellular carcinoma who had Child-Pugh B7 liver function.

Rhenium Obisbemeda Demonstrates Safety and Feasibility in Leptomeningeal Metastases

August 12th 2024

Rhenium obisbemeda proved feasible and safe for patients with leptomeningeal metastases in an interim analysis of the phase 1 ReSPECT-LM trial.

The AHN Cancer Institute is Leading the Way in Pancreatic Cancer Care, Offering an Early Intervention Clinic, Clinical Trials, and Comprehensive Support

August 12th 2024

At the Allegheny Health Network Cancer Institute, specialists are turning the tide on pancreatic cancer through early intervention and collaboration.

Devimistat Plus Modified FFX Misses the Mark in Metastatic Pancreatic Adenocarcinoma

August 12th 2024

Devimistat and modified fluorouracil, oxaliplatin, irinotecan, and leucovorin did not significantly improve short- or long-term outcomes over standard-dose FFX in metastatic pancreatic adenocarcinoma

RLY-2608 Uses PI3Kα Mutant–Specific Inhibition to More Safely Treat Breast Cancer and Other Solid Tumors

August 12th 2024

Experts provide insights on the first-in-human phase 1 ReDiscovertrial trial, evaluating the mutant-selective PI3Kα inhibitor RLY-2608, which is currently enrolling patients.

Sonrotoclax/Zanubrutinib Leads to Durable Responses in R/R CLL/SLL

August 12th 2024

Stephen Opat, MBBS, discusses data for sonrotoclax plus zanubrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

Dealing With Progression in HR+/HER2– mBC: Could a CDK4/6 Inhibitor Swap be the Solution?

August 11th 2024

Sarah Sammons, MD, discusses treating beyond progression and novel research on PI3K inhibitors in HR-positive, HER2-negative metastatic breast cancer.

Trastuzumab Deruxtecan Demonstrates Activity in HER2-Expressing Biliary Tract Cancer

August 10th 2024

Trastuzumab deruxtecan elicited responses in patients with HER2-positive biliary tract cancer, according to data from a single-arm, phase 2 trial.

Improved Patient Selection Will Pave the Way for ADC Optimization in HER2-Low and -Ultralow Breast Cancer

August 9th 2024

Erika P. Hamilton, MD, discusses the implications of the DESTINY-Breast06 trial for patients with HER2-low and -ultralow breast cancer.

RPS-Optimized Checkpoint Inhibition Bolsters pCR in Patients With Select Rare Breast Cancers

August 9th 2024

High pCR rates were observed for patients with uncommon breast cancer subtypes who received response-predictive subtype–optimized therapy.

Communication Is Key for Prioritizing Patients and Personalizing PDAC Care

August 9th 2024

Tilak Sundaresan, MD, and Nicole S. Evans, MD, discuss the implications of a study evaluating reasons for non-treatment among patients with PDAC.

Enfortumab Vedotin/Pembrolizumab Does Not Negatively Impact QOL in Metastatic Urothelial Cancer

August 9th 2024

Enfortumab vedotin plus pembrolizumab improved survival vs chemotherapy with no QOL detriment in previously untreated metastatic urothelial cancer.

Fox Chase Cancer Center Welcomes Dr. Michelle Pedersen

August 9th 2024

Fox Chase Cancer Center is pleased to announce the hiring of Michelle Pedersen, DO, as a hospitalist and Assistant Professor in the Division of Hospital Medicine within the Department of Medicine.

T-Cell Therapy Deltacel Elicits Early Safety and Efficacy in NSCLC

August 9th 2024

Deltacel generated early signals of clinical efficacy in patients with metastatic non–small cell lung cancer who have not responded to standard therapies.

Observational REVEAL Study Highlights Potential Risk Factors for Disease Transformation in Polycythemia Vera

August 9th 2024

Michael R. Grunwald, MD, discusses findings from a real-world observational study of risk factors related to disease progression in polycythemia vera.